FDA approves rapid-acting insulin for pump use



The FDA expanded the indication for insulin aspart injection 100 U/mL to include use in insulin infusion pumps for the improvement of glycemic response in adults with type 1 and type 2 diabetes, according to a press release from Novo Nordisk.
The FDA approved insulin aspart (Fiasp), a rapid-acting injection, in 2017 for use by IV infusion under supervision by a health care professional or by subcutaneous multiple daily injection (MDI) in adults with diabetes. The insulin aspart injection was a new formulation of NovoLog that includes niacinamide, which helps increase the speed of insulin



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.